A GRIPPing Story? Use of the GRIPP2 Checklist for Reporting Patient and Public Involvement in Research

POSTER #20


Karen Woolley[a,b,c] (ORCID: 0000-0003-4626-7723), Amanda Boughey[d], Sarah McSorley[d], Simon R. Stones[c-f] (ORCID: 0000-0002-5943-1310), Jacqui Oliver[d]

[a]Adjunct Professor, University of Queensland, Brisbane, Australia; [b]Adjunct Professor, University of the Sunshine Coast, Sippy Downs, Australia; [c]Caregiver author; [d]Envision Pharma Group, Wilmslow, Cheshire, UK; [e]Patient author; [f]Amica Scientific, Stockport, Greater Manchester, UK

ENVISION PHARMA GROUP

Key Takeaway

The GRIPP2 guidelines are rarely mentioned (2%) in PPI* publications, limiting evidence-based best practice for PPI



PPI refers to research being carried out "with" or "by" members of the public rather than "to", "about", or "for" them[1]

National Institute for Health and Care Research (NIHR). 2024[1]

Background

- The original Guidance for Reporting Involvement of Patients and the Public (GRIPP)[2] and the updated GRIPP2 checklists[3,4] were developed to enhance the reporting of patient and public involvement (PPI) in research
- There are 2 GRIPP2 checklists:
  - Long form: 34 items; for when PPI is the primary focus of the research
  - Short form: 5 items; for when PPI is not the primary focus of the research

GRIPP2 aims *"...to improve the quality, transparency, and consistency of the international patient and public involvement (PPI) evidence base..."*

Staniszewska S, et al. 2017[3,4]

- Stakeholders involved in publishing PPI research (eg, authors, publication professionals, journal editors, and publishers) could support the use and aims of GRIPP2
- However, real-world evidence on how GRIPP2 is being used is limited[5]


Objectives

We investigated:

1. How have PPI publications changed over time?
2. How many PPI publications mention GRIPP2?
3. What were the characteristics of PPI publications mentioning GRIPP2?
4. How do GRIPP2 items compare with certain journal requirements for reporting PPI?

Methods


- We searched PubMed from inception to identify PPI publications and then generated a dataset of PPI articles following publication of GRIPP2



Results

1. How have PPI publications changed over time?

- The number of PPI publications has increased rapidly, particularly since 2017



2. How many PPI publications mention GRIPP2?

- Almost all PPI publications, published since GRIPP2, did **not** mention GRIPP2



3. What were the characteristics of PPI publications mentioning GRIPP2?

- Of the 28 PPI publications mentioning GRIPP2, 5 did not report research results (article types: methods; protocol; letter) and 3 were not available with free full text

Characteristics of free full-text research PPI publications with real-world use of GRIPP2 (n = 20)

Article type	Most frequent: Research article (11; 55%)
Country of first author	Most frequent: UK (12; 60%)
Country of funder	Most frequent: UK (9; 45%)
Therapeutic area	Most frequent: General (not therapeutic area specific) (9; 45%)
Language	Most frequent: English (20; 100%)
Patient authorship[†]	8; 40%
Medical writer use	0; 0%
Industry sponsor	0; 0%
Use of GRIPP2 as a keyword	1; 5%

[†] Patient authors may encourage the use of GRIPP2 or work with those who do.[6] Patient authorship (40%) in these PPI publications is relatively high in contrast to patient authorship in patient experience publications (0.2%).[7]

- Of these 20 publications:
  - 14 (70%) used GRIPP2 for purposes other than PPI reporting (eg, guide data collection; assess data quality); 6 (30%) used GRIPP2 to report on PPI (eg, how PPI influenced the study)
  - 8 (40%) included a GRIPP2 form with the publication
    - 6 (75%) as a supplement; 2 (25%) within the publication
    - 5 (63%) completed the form by referring only to page numbers, 2 (25%) included full-text responses, and 1 (12%) had both full-text and page numbers
    - 5 (63%) used the short form; 3 (37%) used the long form
      - Form choice may have been inappropriate; of the 5 publications with a short form, 4 (80%) had PPI as a primary focus but did not use the recommended long form

4. How do GRIPP2 items compare with certain journal requirements for reporting PPI?

- The specific requirements for PPI reporting differ between the 2 versions of GRIPP2 and between the requirements issued by some journals[8,9]
- If variations continue, inefficiencies and inconsistencies in PPI reporting are likely

Limitations

- Results are limited by PubMed's database and searchability functions and by analysing PPI reporting guidelines from 2 journals[8,9]

Conclusions

- Real-world evidence indicates that the aims of GRIPP2 are not being met
  - Although PPI publications are increasing rapidly, GRIPP2 is rarely mentioned
  - If used, the GRIPP2 form is being completed in variable, potentially inefficient and inappropriate, ways
  - Publication professionals could help authors use GRIPP2 for PPI publications

GRIPP2 Report Card

PPI evidence base

GRIPP2	Quality	Transparency	Consistency	
Aims	✓	✓	✓	= Strong
Use	✗	✗	✗	= Weak

Has the time come?

"As the field of PPI develops, we expect further development of GRIPP2 to refine and update the guidance"

Brett J, et al. 2017[10]

- A multistakeholder-driven update to GRIPP2 and consideration of incentives for standardised, complete, transparent, and efficient reporting may be warranted[5,11-13]

Please scan this QR code to hear an audio summary of the lead author's perspectives

Contact: Professor Karen L. Woolley; kwoolley535@gmail.com

References

1. NIHR. https://sites.google.com/nihr.ac.uk/pi-standards/standards/definitions. Accessed March 19, 2024. 2. Staniszewska S, et al. *Int J Technol Assess Health Care*. 2011;27(4):391-399. 3. Staniszewska S, et al. *BMJ*. 2017;358:j3453. 4. Staniszewska S, et al. *Res Involv Engagem*. 2017;3:13. 5. Jones J, et al. *Res Involv Engagem*. 2021;7(1):52. 6. Vanderhout S, et al. *J Clin Epidemiol*. 2023;164:35-44. 7. Lobban D, et al. *Curr Med Research Opin*. 2023;39(suppl 1):5-39. 8. The BMJ. https://www.bmj.com/sites/default/files/attachments/resources/2018/03/PPI_in_Research.pdf. Accessed December 19, 2024. 9. Davis S, et al. *Lancet Psychiatry*. 2024;11(1):8-9. 10. Brett J, et al. *BMJ Open*. 2017;22;7(10):e016948. 11. Woolley KL. https://www.linkedin.com/posts/prof-karen-woolley_reporting-lived-experience-work-activity-7149973934652731393-ZKrd?utm_%20source=share&utm_medium=member_desktop. Accessed March 19, 2024. 12. Woolley KL. https://x.com/KWProScribe/status/1744210454434680878. Accessed March 19, 2024. 13. Woolley KL, et al. Patient authorship of medical research publications – an evolution, revolution, and solution? *J Learned Publishing*. 2024;37:e1607.

Disclosures and Acknowledgments

All authors participated in the research, were actively involved in preparing the abstract, and have approved the final poster. KW is a consultant to, and shareholder in, Envision Pharma Group. AB, SM, and JO are employees of, and own share options in, Envision Pharma Group, a healthcare communications company that is funded by pharmaceutical companies. SRS is an employee of Amica Scientific, a healthcare communications company that is funded by pharmaceutical companies, was an employee of Envision Pharma Group at the time when the study was conducted, has received honoraria from Taylor & Francis, Sage, The Kennedy Trust and The National Institute for Health and Care Research, is a trustee of RAiISE (a charitable incorporated organisation registered in England and Wales Number 1180704), is a member of the ISMPP Patient Engagement Task Force, and is the Chair-elect of the EULAR PARE Committee. Editorial and graphical support were provided by Miranda Dixon and Sally Logan of Envision Pharma Group. This poster was previously presented at the 20th Annual Meeting of the International Society for Medical Publication Professionals (29 April to 1 May 2024)

Presented at the 2025 European Meeting of the International Society for Medical Publication Professionals (27–29 January 2025; London, United Kingdom)